---
title: 'Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma:
  a retrospective study from the EBMT transplant complications and lymphoma working
  party'
date: '2023-10-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37828980/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231013180808&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19
  chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel;
  n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for
  Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade
  3 organ toxicities during the first 100 days after CAR-T was low and the most frequent
  were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%).
  The ...'
disable_comments: true
---
We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The ...